^
Association details:
| Biomarker: | ALK positive |
|---|---|
| Cancer: | T Cell Non-Hodgkin Lymphoma |
| Drug: | cemsidomide (CFT7455) (IKZF1 degrader, IKZF3 degrader) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
233 | CFT7455: A novel, IKZF1/3 degrader that demonstrates potent tumor regression in a spectrum of NHL xenograft models
Published date:
06/09/2021
Excerpt:
CFT7455 showed dose dependent efficacy in the ALK- ALCL xenograft model, DL40, from 3-100 µg/kg with regressions at doses ≥10 µg/kg.
